On April 21, 2021 Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported that the Board of Directors has approved the Company’s financial statements for 2020 (Press release, Vaccibody, APR 21, 2021, View Source [SID1234578297]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s annual accounts for the financial year 2020, including the financial statements and annual report, are together with the auditor’s report attached to this announcement. Vaccibody’s annual report 2020 contains the first annual accounts where the financial statements have been prepared in accordance with IFRS (International Financial Reporting Standards). The financial statements are presented in United States dollar (USD). The annual report 2020 is also available at the Company’s website, View Source